ICU Medical (ICUI) Tops Q1 EPS by 122c, Beats on Revenue
Get Alerts ICUI Hot Sheet
EPS Growth %: -9.0%
Financial Fact:
Basic (in shares): 16.2M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
ICU Medical (NASDAQ: ICUI) reported Q1 EPS of $1.68, $1.22 better than the analyst estimate of $0.46. May not be comparable. Revenue for the quarter came in at $248.1 million versus the consensus estimate of $237.12 million.
First Quarter 2017 Results
First quarter 2017 revenue was $247.7 million, compared to $89.9 million in the same period last year. GAAP gross profit for the first quarter of 2017 was $88.9 million, as compared to $49.2 million in the same period last year. GAAP gross margin for the first quarter of 2017 was 36%, as compared to 55% in the same period last year. GAAP net income for the first quarter of 2017 was $55.9 million, or $2.86 per diluted share, as compared to GAAP net income of $18.2 million, or $1.08 per diluted share, for the first quarter of 2016, which were both adjusted from the previously announced adoption of FASB ASU 2016-09, Improvements to Employee Share-based Payment Accounting, effective January 1, 2016.
Adjusted net sales for the first quarter of 2017 was $248.1 million. Adjusted gross profit for the first quarter of 2017 was $111.0 million. Adjusted gross margin for the first quarter of 2017 was 45%. Adjusted diluted earnings per share for the first quarter of 2017 were $1.68 as compared to $1.26 for the first quarter of 2016. Also, adjusted EBITDA was $50.1 million for the first quarter of 2017 as compared to $32.7 million for the first quarter of 2016.
For earnings history and earnings-related data on ICU Medical (ICUI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Freedom Broker Starts Unity Bancorp (UNTY) at Hold
- MotorK names Roy Toren to board as Helen Protopapas resigns
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share